Multidrug therapy for polycystic kidney disease: A review and perspective

American Journal of Nephrology

Volumn 37, Issue 2, 2013, Pages 175-182

  Aguiari, Gianluca ^a   Catizone, Luigi ^b   Del Senno, Laura ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b S ANNA HOSPITAL   (Italy)

Author keywords

and EGFR signaling; Autosomal dominant polycystic kidney disease; cAMP; Cl IB MECA; mTOR; Therapy

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; BOSUTINIB; CYCLIC AMP; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MOZAVAPTAN; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL] 2 BUTYNAMIDE; OCTREOTIDE; PELITINIB; RAPAMYCIN; SORAFENIB; TRIPTOLIDE;

CALCIUM SIGNALING; CALCIUM TRANSPORT; CELL PROLIFERATION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY POLYCYSTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; REVIEW;

EID: 84874011475     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000346812     Document Type: Review

References (53)

1. Gabow PA: Autosomal dominant polycystic kidney disease. N Engl J Med 1993; 22: 511-512.
2. Zheleznova NN, Wilson PD, Staruschenko A: Epidermal growth factor-mediated proliferation and sodium transport in normal and PKD epithelial cells. Biochim Biophys Acta 2011; 1812: 1301-1313.
3. Belibi FA, et al: Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int 2004; 66: 964-973.
4. Shillingford JM, et al: The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 2006; 103: 5466-5471.
5. Torres VE, et al, the TEMPO 3: 4 Trial Investigators: Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012 (E-pub ahead of print).
6. Hogan MC, et al: Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 2010; 21: 1052-1061.
7. Serra AL, et al: Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363: 820-829.
8. Walz G, et al: Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363: 830-840.
9. Hanaoka K, et al: Co-assembly of polycystin-1 and-2 produces unique cation-permeable currents. Nature 2000; 408: 990-994.
10. Nauli SM, et al: Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet 2003; 33: 129-137.
11. Praetorius HA, Spring KR: Bending the MDCK cell primary cilium increases intracellular calcium. J Membr Biol 2001; 184: 71-79.
12. Choi YH, et al: Polycystin-2 and phosphodiesterase 4C are components of a ciliary A-kinase anchoring protein complex that is disrupted in cystic kidney diseases. Proc Natl Acad Sci USA 2011; 108: 10679-10684.
13. Aguiari G, et al: Novel role for polycystin-1 in modulating cell proliferation through calcium oscillations in kidney cells. Cell Prolif 2008; 41: 554-573.
14. Yamaguchi T, et al: Cyclic AMP activates BRaf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int 2003; 63: 1983-1994.
15. Terryn S, Ho A, Beauwens R, Devuyst O: Fluid transport and cystogenesis in autosomal dominant polycystic kidney disease. Biochim Biophys Acta 2011; 1812: 1314-1321.
16. Brook-Carter PT, et al: Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease-a contiguous gene syndrome. Nat Genet 1994; 8: 328-332.
17. Dere R, Wilson PD, Sandford RN, Walker CL: Carboxy terminal tail of polycystin-1 regulates localization of TSC2 to repress mTOR. PLoS One 2010; 5:e9239.
18. Weimbs T: Regulation of mTOR by polycystin-1: is polycystic kidney disease a case of futile repair? Cell Cycle 2006; 5: 2425-2429.
19. Distefano G, et al: Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1. Mol Cell Biol 2009; 29: 2359-2371.
20. Wilson PD: A plethora of epidermal growth factor-like proteins in polycystic kidneys. Kidney Int 2004; 65: 2441-2442.
21. Lowden DA, Lindemann GW, Merlino G, Barash BD, Calvet JP, Gattone VH: Renal cysts in transgenic mice expressing transforming growth factor-α. J Lab Clin Med 1994; 124: 386-394.
22. Aguiari G, et al: Polycystin-1 regulates amphiregulin expression through CREB and AP1 signalling: implications in ADPKD cell proliferation. J Mol Med 2012; 90: 1267-1282.
23. Du J, Wilson PD: Abnormal polarization of EGF receptors and autocrine stimulation of cyst epithelial growth in human ADPKD. Am J Physiol 1995; 269:C487-C495.
24. Wilson SJ, et al: Inhibition of HER-2 (neu/ ErbB2) restores normal function and structure to polycystic kidney disease epithelia. Biochim Biophys Acta 2006; 1762: 647-655.
25. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH: Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 2004; 10: 363-364.
26. Reif GA, Yamaguchi T, Nivens E, Fujiki H, Pinto CS, Wallace DP: Tolvaptan inhibits ERK-dependent cell proliferation, Cl-secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. Am J Physiol Renal Physiol 2011; 301:F1005-F1013.
27. Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF: Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3′,5′-cyclic monophosphate. Gastroenterology 2007; 132: 1104-1116.
28. Hogan MC, et al: Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrol Dial Transplant 2012; 27: 3532-3539.
29. Caroli A, et al: effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol 2010; 5: 783-789.
30. Aguiari G, et al: Deficiency of polycystic kidney disease-1 gene (PKD1) expression increases A 3 adenosine receptors in human renal cells: implications for cAMP-dependent signalling and proliferation of PKD1-mutated cystic cells. Biochim Biophys Acta 2009; 1792: 531-540.
31. Yamaguchi T, Reif GA, Calvet JP, Wallace DP: Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells. Am J Physiol Renal Physiol 2010; 299:F944-F951.
32. Yamaguchi T, et al: cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int 2000; 57: 1460-1471.
33. Shibazaki S, et al: Cyst formation and activation of the extracellular regulated kinase pathway after kidney-specific inactivation of Pkd1. Hum Mol Genet 2008; 17: 1505-1516.
34. Omori S, et al: Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease. J Am Soc Nephrol 2006; 17: 1604-1614.
35. Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wuthrich RP: Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 2006; 21: 598-604.
36. Wu M, Wahl PR, Le Hir M, Wackerle-Men Y, Wuthrich RP, Serra AL: Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press Res 2007; 30: 253-259.
37. Perico N, et al: Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol 2010; 21: 1031-1040.
38. Grantham JJ, Bennett WM, Perrone RD: mTOR inhibitors and autosomal dominant polycystic kidney disease. N Engl J Med 2011; 364: 286-289.
39. Torres VE, et al: EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats. Kidney Int 2003; 64: 1573-1579.
40. Gao J, et al: Curcumin inhibits renal cyst formation and enlargement in vitro by regulating intracellular signaling pathways. Eur J Pharmacol 2011; 654: 92-99.
41. Leonhard WN, et al: Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model. Am J Physiol Renal Physiol 2011; 300:F1193-F1202.
42. Elliott J, Zheleznova NN, Wilson PD: c-Src inactivation reduces renal epithelial cell-matrix adhesion, proliferation, and cyst formation. Am J Physiol Cell Physiol 2011; 301:C522-C529.
43. Leuenroth SJ, et al: Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease. Proc Natl Acad Sci USA 2007; 104: 4389-4394.
44. Leuenroth SJ, et al: Triptolide reduces cystogenesis in a model of ADPKD. J Am Soc Nephrol 2008; 19: 1659-1662.
45. Mitobe M, et al: Clinical effects of calcium channel blockers and renin-angiotensin-aldosterone system inhibitors on changes in the estimated glomerular filtration rate in patients with polycystic kidney disease. Clin Exp Nephrol 2010; 14: 573-577.
46. Torres VE, et al: Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011; 6: 640-647.
47. Barash I, Ponda MP, Goldfarb DS, Skolnik EY: A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2010; 5: 693-697.
48. Novalic Z, et al: Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease. J Am Soc Nephrol 2012; 23: 842-853.
49. Chang MY, Ong AC: Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects. Nephron Clin Pract 2012; 120:c25-c34.
50. Schmid K, et al: Dual inhibition of EGFR and mTOR pathways in small cell lung cancer. Br J Cancer 2010; 103: 622-628.
51. Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW: Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer. Clin Cancer Res 2011; 17: 6482-6489.
52. Lin JT, et al: Differential mTOR and ERK pathway utilization by effector CD4 T cells suggests combinatorial drug therapy of arthritis. Clin Immunol 2012; 142: 127-138.
53. Marcotte R, Zhou L, Kim H, Roskelly CD, Muller WJ: c-Src associates with ErbB2 through an interaction between catalytic domains and confers enhanced transforming potential. Mol Cell Biol 2009; 29: 5858-5871.